CIBC Private Wealth Group
LVTX

CIBC Private Wealth Group’s LAVA Therapeutics LVTX Stock Holding History

CIBC Private Wealth Group’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,000
Closed -$6.12K – 3203
2024
Q4 		$6.12K Hold
6,000
– – ﹤0.01% 2418
2024
Q3 		$9.96K Hold
6,000
– – ﹤0.01% 2405
2024
Q2 		$11.1K Hold
6,000
– – ﹤0.01% 2259
2024
Q1 		$20K Buy
+6,000
New +$13.2K ﹤0.01% 2048

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

CIBC Private Wealth Group's LVTX Position: Q1 2025 in Review

CIBC Private Wealth Group sold out of LAVA Therapeutics (LVTX) in Q1 2025, closing a stake of 6,000 shares — an estimated $6.12K sold.

CIBC Private Wealth Group first reported a position in LVTX in Q1 2024 and held it in 4 quarters. The position peaked at $20K in Q1 2024. 20 funds tracked by Wall St. Rank hold LVTX as of Q1 2025.

  • CIBC Private Wealth Group reported no remaining LAVA Therapeutics position as of Q1 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 6,000 LAVA Therapeutics shares in Q1 2025, an estimated $6.12K.
  • CIBC Private Wealth Group first reported a position in LAVA Therapeutics in Q1 2024 and held it in 4 quarters.
  • CIBC Private Wealth Group's LAVA Therapeutics position peaked at $20K in Q1 2024.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2025.

Based on CIBC Private Wealth Group's 13F filing for Q1 2025, filed 14 May 2025.